Development of proteasome inhibitors as research tools and cancer drugs

View/ Open
Author
Published Version
https://doi.org/10.1083/jcb.201210077Metadata
Show full item recordCitation
Goldberg, Alfred L. 2012. Development of proteasome inhibitors as research tools and cancer drugs. The Journal of Cell Biology 199(4): 583-588.Abstract
The proteasome is the primary site for protein degradation in mammalian cells, and proteasome inhibitors have been invaluable tools in clarifying its cellular functions. The anticancer agent bortezomib inhibits the major peptidase sites in the proteasome’s 20S core particle. It is a “blockbuster drug” that has led to dramatic improvements in the treatment of multiple myeloma, a cancer of plasma cells. The development of proteasome inhibitors illustrates the unpredictability, frustrations, and potential rewards of drug development but also emphasizes the dependence of medical advances on basic biological research.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494858/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179739
Collections
- HMS Scholarly Articles [17714]
Contact administrator regarding this item (to report mistakes or request changes)